

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 54

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wild Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–91) and Recommended (1–52) International Nonproprietary Names can be found in *Cumulative List No. 11, 2004* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 54

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–91) et recommandées (1–52) dans la *Liste récapitulative No. 11, 2004* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 54

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–91) y Recomendadas (1–52) se encuentran reunidas en *Cumulative List No. 11, 2004* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:
Recommended INN

Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada

acidum salclobuzicum

salclobuzic acid

4-(4-chloro-2-hydroxybenzamido)butanoic acid


acide salclobuzique

acide 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoïque

ácido salclobúxico

ácido 4-[(4-cloro-2-hidroxibenzoil)amino]butanoico

C₁₁H₁₂ClNO₄



ancrivirocum

ancriviroc

3-({4-[(Z)-(4-bromophenyl)(ethoxyimino)methyl]-4'-methyl-[1,4'-bipiperidin]-1'-yl}carbonyl)-2,4-dimethylpyridine-1-oxide


ancriviroc

4-[(Z)-(4-bromophényl)(éthoxyimino)méthyl]-1'-[(2,4-diméthyl-1-oxypyridin-3-yl)carbonyl]-4'-méthyl-1,4'-bipéridinyle

ancriviroc

4-[(Z)-(4-bromofenil)(etoxiimino)metil]-1'-[(2,4-dimetil-1-oxidopiridin-3-il)carbonil]-4'-metil-1,4'-bipéridinilo

C₂₈H₃₇BrN₄O₃



aplindorum

aplindore



(2S)-2-[(benzylamino)methyl]-2,3,7,9-tetrahydro-8H-1,4-dioxino-[2,3-e]indol-8-one

aplindore

(2S)-2-[(benzylamino)méthyl]-2,3,7,9-tétrahydro-8H-1,4-dioxino-[2,3-e]indol-8-one

aplindor

(2S)-2-[(bencilamino)metil]-2,3,7,9-tetrahidro-8H-1,4-dioxino-[2,3-e]indol-8-ona



atilmotinum
atilmotin



N-[(2*S*)-3-phenyl-2-(trimethylazaniumyl)propanoyl]-L-valyl-L-prolyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-tyrosylglycyl-L-glutamyl-L-leucyl-L-glutamyl-D-arginyl-L-leucyl-L-lysineamide

atilmotine

N-[(2*S*)-3-phényl-2-(triméthylammonio)propanoïl]-L-valyl-L-prolyl-L-isoleucyl-L-phénylalanil-L-thréonyl-L-tyrosylglycyl-L-glutamyl-L-leucyl-L-glutamyl-D-arginyl-L-leucyl-L-lysineamide

atilmotina

N-[(2*S*)-3-fenil-2-(trimetilamonio)propanoïl]-L-valil-L-prolil-L-isoleucil-L-fenilalanil-L-treonil-L-tirosilglicil-L-glutamil-L-leucil-L-glutaminiil-D-arginil-L-leucil-L-lisineamida



Leu—Gln—D-Arg—Leu—Lys—NH₂

avanafilum
avanafil



4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2*S*)-2-(hydroxymethyl)pyrrolidin-1-yl]-*N*-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide

avanafil

4-[(3-chloro-4-méthoxybenzyl)amino]-2-[(2*S*)-2-(hydroxyméthyl)=pyrrolidin-1-yl]-*N*-(pyrimidin-2-ylméthyl)pyrimidine-5-carboxamide

avanafilo

4-[(3-cloro-4-metoxibencil)amino]-2-[(2*S*)-2-(hidroximetil)pirrolidin-1-il]-*N*-(pirimidin-2-ilmetil)pirimidina-5-carboxamida



balicatibum


balicatib

N-{1-[(cyanomethyl)carbamoyl]cyclohexyl}-4-(4-propylpiperazin-1-yl)benzamide

balicatib

N-[1-[(cyanométhyl)carbamoyl]cyclohexyl]-4-(4-propylpipérazin-1-yl)benzamide

balicatib

N-[1-[(cianometil)carbamoi]ciclohexil]-4-(4-propilpiperazin-1-il)benzamidaC₂₃H₃₃N₅O₂**becatecarinum**


becatecarin

1,11-dichloro-6-[2-(diethylamino)ethyl]-12-(4-*O*-methyl-β-*D*-glucopyranosyl)-12,13-dihydro-5*H*-indolo[2,3-*a*]pyrrolo-[3,4-*c*]carbazole-5,7(6*H*)-dione

bécatécarine

1,11-dichloro-6-[2-(diéthylamino)éthyl]-12-(4-*O*-méthyl-β-*D*-glucopyranosyl)-12,13-dihydro-5*H*-indolo[2,3-*a*]pyrrolo-[3,4-*c*]carbazole-5,7(6*H*)-dione

becatecarina

1,11-dicloro-6-[2-(dietilamino)etil]-12-(4-*O*-metil-β-*D*-glucopiranosil)-12,13-dihidro-5*H*-indolo[2,3-*a*]pirrolo[3,4-*c*]carbazol-5,7(6*H*)-dionaC₃₃H₃₄Cl₂N₄O₇

becocalcidiolum


becocalcidiol

(1*R*,3*R*)-4-(2-((1*R*,3*aS*,7*aR*)-1-[(2*S*)-butan-2-yl]-7*a*-methyloctahydro-4*H*-inden-4-ylidene)ethylidene)-2-methylidencyclohexane-1,3-diol

bécocalcidiol

(1*R*,3*R*)-2-méthylidène-5-[(2*E*)-2-[(1*R*,3*aS*,7*aR*)-7*a*-méthyl-1-[(1*S*)-1-méthylpropyl]octahydro-4*H*-indén-4-ylidène]éthylidène]=cyclohexane-1,3-diol

becocalcidiol

(1*R*,3*R*)-2-metilideno-5-[(2*E*)-2-[(1*R*,3*aS*,7*aR*)-7*a*-metil-1-[(1*S*)-1-metilpropil]octahidro-4*H*-inden-4-ilideno]etilideno]=ciclohexano-1,3-diolC₂₃H₃₆O₂**bemotrizinolum**

bemotrizinol


2,2'-[6-(4-methoxyphenyl)-1,3,5-triazine-2,4-diyl]bis-[5-[(2-ethylhexyl)oxy]phenol]

bémotrizinol

2,2'-[6-(4-méthoxyphényl)-1,3,5-triazine-2,4-diyl]bis-[5-[(2-éthylhexyl)oxy]phénol]

bemotrizinol

2,2'-[6-(4-metoxifenil)-1,3,5-triazina-2,4-diil]bis[5-[(2-etilhexil)=oxi]fenol]

C₃₈H₄₉N₃O₅

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.